[1]关芳 康雅隆 谭娟娟 齐鸿飞 秦墁 王若楠 王海芳.干扰小RNA抗高血压药zilebesiran的研究进展[J].心血管病学进展,2024,(12):1099.[doi:10.16806/j.cnki.issn.1004-3934.2024.12.010]
　GUAN FangKANG YalongTAN JuanjuanQI HongfeiQIN ManWANG RuonanWANG Haifang.siRNA Antihypertensive Drug Zilebesiran[J].Advances in Cardiovascular Diseases,2024,(12):1099.[doi:10.16806/j.cnki.issn.1004-3934.2024.12.010]
点击复制

干扰小RNA抗高血压药zilebesiran的研究进展()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2024年12期
页码:
1099
栏目:
综述
出版日期:
2024-12-25

文章信息/Info

Title:
siRNA Antihypertensive Drug Zilebesiran
作者:
关芳 康雅隆 谭娟娟 齐鸿飞 秦墁 王若楠 王海芳
(陕西中医药大学 陕西省及咸阳市中西医结合心血管病防治重点实验室,陕西 咸阳 712000)
Author(s):
GUAN FangKANG YalongTAN JuanjuanQI HongfeiQIN ManWANG RuonanWANG Haifang
(Shaanxi University of Chinese Medicine,Shaanxi Province and Xianyang Key Laboratory of Integrative Traditional Chinese and Western Medicine for the Prevention and Treatment of Cardiovascular Diseases,Xianyang 712000,Shaanxi,China)
关键词:
zilebesiran; 高血压; 干扰小RNA; 血管紧张素原
Keywords:
Zilebesiran; Hypertension; Small interfering RNA; Angiotensinogen
DOI:
10.16806/j.cnki.issn.1004-3934.2024.12.010
摘要:
高血压是心脑血管疾病的重要危险因素之一。目前中国的高血压发病率高，但知晓率、诊断率、治疗率相对较低。高血压发病机制复杂，尚不完全清楚，且具有较大的个体差异性。目前西医治疗以口服抗高血压药为主要手段，用药间隔时间短、依从性差，部分患者联合用药后血压控制仍欠佳。zilebesiran是一类新型、尚处于临床研究阶段的干扰小RNA抗高血压药，能够特异性阻断肝脏血管紧张素原信使RNA的表达，从而减少肝脏血管紧张素原的合成，实现降压目的。该药物的作用靶点较传统抗高血压药更为上游，效果更为全面、强效，且半衰期长，用药频次明显减低，当前研究结果提示其短期应用具有良好的耐受性及安全性。现旨在介绍zilebesiran的作用机制和临床试验的初步结果，包括疗效及安全性，以期提高国内相关领域研究人员对该药的全面深入认识。
Abstract:
Hypertension is one of the important risk factors of cardiovascular and cerebrovascular diseases. At present,the incidence rate of hypertension in China is high,while the awareness rate,diagnosis rate and treatment rate are relatively low. The pathogenesis of hypertension is complex,not fully understood,and has significant individual differences. At present,oral antihypertensive drugs are the main treatment method in Western medicine,with short medication intervals and poor compliance. Blood pressure control is still not enough in some patients after combination therapy. Zilebesiran is a new type of small interfering RNA antihypertensive drug that is still in the clinical research stage. It is proposed to specifically prevent the gene expression of liver angiotensinogen messenger RNA,thereby reducing the synthesis of angiotensinogen and achieving antihypertensive goals. The drug acts at a upstream site of traditional antihypertensive drugs,with a more comprehensive and potent effect,long half-life,and significantly reduced frequency of dosing. Current research findings suggest that its short-term use has good tolerability and safety. The aim is to introduce the mechanism of action and the preliminary results of clinical trials of zilebesiran ,including its efficacy and safety,in order to enhance the comprehensive understanding of this drug among researchers in relevant fields in China.

参考文献/References:

[1] 中国高血压防治指南修订委员会,中国高血压联盟,中国医疗保健国际交流促进会高血压病学分会,等. 中国高血压防治指南(2024年修订版)[J]. 中华高血压杂志(中英文),2024,32(07):603-700.
[2] Desai AS,Webb DJ,Taubel J,et al. Zilebesiran,an RNA interference therapeutic agent for hypertension[J]. N Engl J Med,2023,389(3):228-238.
[3] 葛俊波,王辰,王建安,等. 内科学:第10版[M]. 北京: 人民卫生出版社,2024.
[4] 罗自强,管又飞,武宇明,等. 生理学:第10版[M]. 北京:人民卫生出版社,2024.
[5] 杨永鑫,任明. 血压变异性及昼夜节律与肾素-血管紧张素-醛固酮系统[J]. 中国临床研究,2014,27(12):1553-1555.
[6] Khan RS ,Frishman WH. Zilebesiran :a promising antihypertensive therapy inhibiting angiotensinogen synthesis[J]. Cardiol Rev,2024.DOI:10.1097/CRD.0000000000000645.
[7] Addison ML ,Ranasinghe P ,Webb DJ. Novel pharmacological approaches in the treatment of hypertension :a focus on RNA-based therapeutics[J]. Hypertension,2023,80(11):2243-2254.
[8] Ranasinghe P ,Addison ML ,Webb DJ. Small interfering RNA therapeutics in hypertension :a viewpoint on vasopressor and vasopressor-sparing strategies for counteracting blood pressure lowering by angiotensinogen-targeting small interfering RNA[J]. J Am Heart Assoc,2022,11(20):e027694.
[9] 张新军. 生物医药治疗高血压的时代曙光初露——评zilebesiran临床研究[J]. 中华高血压杂志(中英文),2024,32(2):101-103.
[10] Liuzzo G ,Volpe M. Silencing liver angiotensinogen synthesis as a novel approach to hypertension management :promises and challenges[J]. Eur Heart J,2023,44(40):4217-4219.
[11] Traber GM ,Yu AM. RNAi-based therapeutics and novel RNA bioengineering technologies[J]. J Pharmacol Exp Ther,2023,384(1):133-154.
[12] 李琛,司笑,李金波,等. 小干扰RNA药物的化学修饰及递送系统[J]. 化学学报,2023,81(9):1240-1254.
[13] Braunwald E. Short interfering RNA :a rapidly developing drug class[J]. Eur Heart J,2022,43(46):4772-4774.
[14] Al MA. Hypertension cure research progress:the use of zilebesiran in hypertension[J]. J Med Clin Studies,2023,6(3):194.
[15] Addison ML ,Ranasinghe P ,Webb DJ. Emerging insights and future prospects for therapeutic application of siRNA targeting angiotensinogen in hypertension[J]. Expert Rev Clin Pharmacol,2023,16(11):1025-1033.
[16] Uijl E ,Ye D ,Ren L ,et al. Conventional vasopressor and vasopressor-sparing strategies to counteract the blood pressure-lowering effect of small interfering RNA targeting angiotensinogen[J]. J Am Heart Assoc,2022,11(15):e026426.
[17] Taubel J ,Desai AS ,Lasko M ,et al. Safety and tolerability of zilebesiran,an RNA interference therapeutic targeting hepatic angiotensinogen synthesis,in obese patients with hypertension[C]. America:American Heart Association Hypertension Scientific Sessions,2023.
[18] Bakris GL ,Saxena M ,Gupta A ,et al. RNA interference with zilebesiran for mild to moderate hypertension:the KARDIA-1 randomized clinical trial[J]. JAMA,2024,331(9):740-749.
[19] Bakris G ,Saxena M ,Gupta A,et al. Sustained blood pressure reduction with the RNA Interference therapeutic zilebesiran:primary results from KARDIA-1,a phase 2 study in patients with hypertension[C]. America :American Heart Association Scientific Sessions,2023.
[20] Surma S ,Oparil S. Zilebesiran－ The first siRNA-based drug in hypertensiology:why is it needed,and will it change the treatment approach of hypertension?[J]. Arterial Hypertension,2024,28:1-11.
[21] Bakris GL ,Desai AS ,Aswad A ,et al. Zilebesiran in combination with a standard-of-care antihypertensive in patients with inadequately controlled hypertension:primary results from the phase 2 KARDIA-2 study[C]. America:The 2024 American College of Cardiology Annual Scientific Session,2024.

相似文献/References:

[1]孙刚,黄冠华,综述.高血压合并心力衰竭的治疗策略[J].心血管病学进展,2016,(2):201.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.027]
　SUN Gang,HUANG Guanhua.Treatment Strategy of Hypertension with Heart Failure[J].Advances in Cardiovascular Diseases,2016,(12):201.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.027]
[2]范贵娟,综述,徐瑞,等.盐敏感性高血压的研究进展[J].心血管病学进展,2016,(4):364.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.010]
　FAN Guijuan,XU Rui.Research Progress of Salt Sensitive Hypertension[J].Advances in Cardiovascular Diseases,2016,(12):364.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.010]
[3]陈源源.钙通道阻滞剂在降压治疗中的应用[J].心血管病学进展,2015,(6):662.[doi:10.3969/j.issn.1004-3934.2015.06.002]
　CHEN Yuanyuan.Application of Calcium Channel Blockers in Hypertension Treatment[J].Advances in Cardiovascular Diseases,2015,(12):662.[doi:10.3969/j.issn.1004-3934.2015.06.002]
[4]张瑞 毛露 孙硕 Dirk Hermann 陈艾东.内皮素-1干预成为高血压治疗新靶点的展望[J].心血管病学进展,2019,(7):969.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.000]
　ZHANG Rui MAO LuSUN ShuoDIRK Hermann CHEN Aidong.The Prospect of Endothelin-1 Intervention as A New Target for the Treatment of Hypertension[J].Advances in Cardiovascular Diseases,2019,(12):969.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.000]
[5]张毅,柳志红.动态血压监测在高血压中的应用现状与问题[J].心血管病学进展,2019,(6):848.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.003]
　ZHANG Yi,LIU Zhihong.Current status and nsolved Pproblems of Ambulatory Blood Pressure Monitoring for the Management of Hypertension[J].Advances in Cardiovascular Diseases,2019,(12):848.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.003]
[6]黄秋瑾 胡蓉.高血压合并糖尿病患者血压控制率和控制目标的探讨[J].心血管病学进展,2019,(7):973.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.002]
　HUANG QiujinHU Rong.Discussion on Blood Pressure Control Rate and Control Target in Patients with Hypertension Complicated with Diabetes[J].Advances in Cardiovascular Diseases,2019,(12):973.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.002]
[7]张旭明 王曦.高血压对认知功能的影响[J].心血管病学进展,2019,(7):977.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.003]
　ZHANG Xuming,WANG Xi.The Relationship Between Hypertension and Cognitive Function[J].Advances in Cardiovascular Diseases,2019,(12):977.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.003]
[8]凌梦军 陈明凌梦军.阻塞性睡眠呼吸暂停低通气综合征与高血压关系的研究进展[J].心血管病学进展,2019,(5):722.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.015]
[9]李波 郭毅 田进文 邓珏琳.高血压合并2型糖尿病的治疗进展[J].心血管病学进展,2019,(9):1196.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.002]
　LI Bo,GUO Yi,TIAN Jinwen,et al.Therapy in Hypertensive Patients with Type 2 Diabetes Mellitus[J].Advances in Cardiovascular Diseases,2019,(12):1196.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.002]
[10]王继航 赵施皓 李开亮 田进文 李玉龙 付士辉 沈明志 邓珏琳.远程医疗在高血压病管理中的研究进展[J].心血管病学进展,2019,(9):1199.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.003]
　WANG Jihang,ZHAO Shihao,LI Kailiang,et al.Telemedicine in Hypertension Management[J].Advances in Cardiovascular Diseases,2019,(12):1199.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.003]

更新日期/Last Update: 2025-01-08